The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis
Purpose: The aim of this meta-analysis is to evaluate the role of Imeglimin in glycemic control (HbA1c & FPG), Homeostatic Model Assessment of β-cell function, pro-insulin to c-peptide ratio and its safety outcomes in patients with type 2 diabetes mellitus. Methods: A thorough literature sea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Diabetes Epidemiology and Management |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666970623000367 |
| _version_ | 1827766397038493696 |
|---|---|
| author | Palaniappan Vinayagam Vengojayparassad Senathipathi Vishnu Shivam Nandhini Velraju |
| author_facet | Palaniappan Vinayagam Vengojayparassad Senathipathi Vishnu Shivam Nandhini Velraju |
| author_sort | Palaniappan Vinayagam |
| collection | DOAJ |
| description | Purpose: The aim of this meta-analysis is to evaluate the role of Imeglimin in glycemic control (HbA1c & FPG), Homeostatic Model Assessment of β-cell function, pro-insulin to c-peptide ratio and its safety outcomes in patients with type 2 diabetes mellitus. Methods: A thorough literature search was performed on PubMed Central, PubMed, Cochrane, Wiley online library databases and efficacy outcomes such as changes in HbA1c, FPG, pro-insulin to c-peptide ratio and HOMA- β were summarized as standardized mean difference and safety outcomes were summarized as odds ratio. (PROSPERO registration no. CRD42023422787). Results: Seven randomized controlled trials conducted on 1,454 patients with type 2 diabetes mellitus were included. Overall the random effects model meta-analysis of standardized mean difference demonstrated that Imeglimin was significantly associated with HbA1c reduction of -0.85% (95% CI -1.08 to -0.62, p<0.00001) with heterogeneity (i2 = 70%, p = 0.002), fasting plasma glucose (FPG) reduction of -0.64 mmol/L (95% CI -0.81 to -0.47, p<0.00001) with non-significant low heterogeneity (i2 = 35%, p = 0.16) and significantly improved HOMA-β function by 0.46 (95% CI 0.25 to 0.67, p<0.0001) compared to control groups with non-significant heterogeneity (i2 = 4%, p = 0.31). Further, the overall analysis of gastrointestinal (GI) adverse events demonstrated that Imeglimin was significantly associated with GI events (OR, 1.83; 95% CI, 1.19 to 2.82; p = 0.006) with no heterogeneity (i2 = 0%, p = 0.80). Conclusion: Our results demonstrated that Imeglimin is significantly associated with the glycemic control (reduction of HbA1c by -0.85% & FPG by -0.64 mmol/L), improved beta cell function (HOMA-β by 0.46) and associated with GI adverse events by 1.83 fold increased odds as compared to controls. |
| first_indexed | 2024-03-11T11:40:27Z |
| format | Article |
| id | doaj.art-5aa7623e8cd24f3d9b3df517a46cb538 |
| institution | Directory Open Access Journal |
| issn | 2666-9706 |
| language | English |
| last_indexed | 2024-03-11T11:40:27Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Diabetes Epidemiology and Management |
| spelling | doaj.art-5aa7623e8cd24f3d9b3df517a46cb5382023-11-10T04:16:30ZengElsevierDiabetes Epidemiology and Management2666-97062023-10-0112100164The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysisPalaniappan Vinayagam0Vengojayparassad Senathipathi1Vishnu Shivam2Nandhini Velraju3Vice President, Association of Physicians of India (National), Mumbai, India; Managing Director and Consultant Physician, Sri Sakthi Vinayakar Multispeciality hospital & Dr. V Palaniappan's Diabetes Specialities Center, Guziliamparai, Dindigul-624703, Tamil Nadu, IndiaDepartment of Diabetology, Coimbatore Medical College and Hospital, Coimbatore-641018, Tamil Nadu, IndiaDepartment of Diabetology, Coimbatore Medical College and Hospital, Coimbatore-641018, Tamil Nadu, India; Vedanadhi, Tamil Nadu, India; Corresponding author: Vishnu Shivam, Department of Diabetology, Coimbatore Medical College and Hospital, Trichy road, Coimbatore-641018, Tamil Nadu, India. Vedanadhi, Kottavady, Salem-636115, Tamil Nadu, India.Department of Obstetrics and Gynecology, Coimbatore Medical College and Hospital, Coimbatore-641018, Tamil Nadu, IndiaPurpose: The aim of this meta-analysis is to evaluate the role of Imeglimin in glycemic control (HbA1c & FPG), Homeostatic Model Assessment of β-cell function, pro-insulin to c-peptide ratio and its safety outcomes in patients with type 2 diabetes mellitus. Methods: A thorough literature search was performed on PubMed Central, PubMed, Cochrane, Wiley online library databases and efficacy outcomes such as changes in HbA1c, FPG, pro-insulin to c-peptide ratio and HOMA- β were summarized as standardized mean difference and safety outcomes were summarized as odds ratio. (PROSPERO registration no. CRD42023422787). Results: Seven randomized controlled trials conducted on 1,454 patients with type 2 diabetes mellitus were included. Overall the random effects model meta-analysis of standardized mean difference demonstrated that Imeglimin was significantly associated with HbA1c reduction of -0.85% (95% CI -1.08 to -0.62, p<0.00001) with heterogeneity (i2 = 70%, p = 0.002), fasting plasma glucose (FPG) reduction of -0.64 mmol/L (95% CI -0.81 to -0.47, p<0.00001) with non-significant low heterogeneity (i2 = 35%, p = 0.16) and significantly improved HOMA-β function by 0.46 (95% CI 0.25 to 0.67, p<0.0001) compared to control groups with non-significant heterogeneity (i2 = 4%, p = 0.31). Further, the overall analysis of gastrointestinal (GI) adverse events demonstrated that Imeglimin was significantly associated with GI events (OR, 1.83; 95% CI, 1.19 to 2.82; p = 0.006) with no heterogeneity (i2 = 0%, p = 0.80). Conclusion: Our results demonstrated that Imeglimin is significantly associated with the glycemic control (reduction of HbA1c by -0.85% & FPG by -0.64 mmol/L), improved beta cell function (HOMA-β by 0.46) and associated with GI adverse events by 1.83 fold increased odds as compared to controls.http://www.sciencedirect.com/science/article/pii/S2666970623000367Anti-diabetic agentsDiabetes mellitusFasting plasma glucoseHbA1cImegliminMeta-analysis |
| spellingShingle | Palaniappan Vinayagam Vengojayparassad Senathipathi Vishnu Shivam Nandhini Velraju The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis Diabetes Epidemiology and Management Anti-diabetic agents Diabetes mellitus Fasting plasma glucose HbA1c Imeglimin Meta-analysis |
| title | The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis |
| title_full | The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis |
| title_fullStr | The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis |
| title_full_unstemmed | The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis |
| title_short | The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis |
| title_sort | role of imeglimin in glycemic control beta cell function and safety outcomes in patients with type 2 diabetes mellitus a comprehensive meta analysis |
| topic | Anti-diabetic agents Diabetes mellitus Fasting plasma glucose HbA1c Imeglimin Meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2666970623000367 |
| work_keys_str_mv | AT palaniappanvinayagam theroleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT vengojayparassadsenathipathi theroleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT vishnushivam theroleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT nandhinivelraju theroleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT palaniappanvinayagam roleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT vengojayparassadsenathipathi roleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT vishnushivam roleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis AT nandhinivelraju roleofimeglimininglycemiccontrolbetacellfunctionandsafetyoutcomesinpatientswithtype2diabetesmellitusacomprehensivemetaanalysis |